Wire · opportunities
Cosentyx Gains FDA Approval for Adults With Polymyalgia Rheumatica
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA has approved Cosentyx (secukinumab) as the first anti-IL-17A biologic treatment for adults with polymyalgia rheumatica who cannot tolerate or respond inadequately to corticosteroids, based on positive results from a Phase 3 trial.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now position your treatment options to include a newly FDA-authorised biologic that offers an alternative to corticosteroids in PMR. This approval opens a sales gate for therapies targeting inflammatory disorders beyond traditional steroid treatments.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics